|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N07XX01
|
|
gptkbp:brand
|
gptkb:Xyrem
gptkb:Xywav
|
|
gptkbp:CASNumber
|
502-85-2
|
|
gptkbp:contraindication
|
gptkb:depression
respiratory depression
alcohol use
|
|
gptkbp:controlledSubstanceSchedule
|
yes
|
|
gptkbp:discoveredBy
|
gptkb:Alexander_Zaytsev
|
|
gptkbp:discoveredIn
|
1874
|
|
gptkbp:drugClass
|
analgesic
sedative
central nervous system depressant
antinarcoleptic
|
|
gptkbp:eliminationHalfLife
|
0.5–1 hour
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C4H7NaO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sodium oxybate
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
|
|
gptkbp:legalStatus
|
gptkb:Schedule_III_(US)
Prescription only
Schedule II (US, raw chemical)
|
|
gptkbp:mechanismOfAction
|
GHB receptor agonist
GABAB receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
coma
seizures
respiratory depression
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (age 7+ in some regions)
|
|
gptkbp:PubChem_CID
|
23663861
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
confusion
nausea
dizziness
headache
enuresis
|
|
gptkbp:synonym
|
GHB sodium salt
gamma-hydroxybutyric acid sodium salt
|
|
gptkbp:UNII
|
Y76GV3JD76
|
|
gptkbp:usedFor
|
narcolepsy
excessive daytime sleepiness
cataplexy
|
|
gptkbp:bfsParent
|
gptkb:N07XX02
|
|
gptkbp:bfsLayer
|
6
|